Boehringer
Boehringer’s lung cancer drug gets EMA nod
September 29, 2014Sales and Marketing Boehringer, IPF, docetaxel, ingelheim, lung cancer, nintedanib
The EMA has issued a positive opinion for the approval of Boehringer Ingelheim’s nintedanib in combination with docetaxel for the …
Boehringer to slash 600 jobs in native Germany
September 24, 2014Manufacturing and Production, Research and Development, Sales and Marketing AMNOG, Boehringer, Germany, Novartis, cuts, mergers, staff
Boehringer Ingelheim is to cut around 600 of its staff in Germany as part of a drive to reduce costs …
Lilly and Boehringer diabetes biosimilar sees EU approval
September 11, 2014Sales and Marketing Boehringer, EU, European Commission, Lantus, Sanofi, diabetes, lilly
Lilly and Boehringer Ingelheim’s insulin glargine product has been shown the green light by the European Commission (EC). The copycat …
InterMune’s IPF drug shines at ERS Congress
September 10, 2014Research and Development, Sales and Marketing Boehringer, ERS, Esbriet, IPF, InterMune, idiopathic pulmonary fibrosis, munich, pirfenidone
InterMune has posted positive data for its lung-scarring drug at this year’s European Respiratory Society Annual Congress 2014 (ERS). Pharmafile …
Ben Venue problems continue for Boehringer
September 2, 2014Manufacturing and Production, Sales and Marketing Ben Venue, Boehringer, fad, german, manufacturing, recall
Boehringer Ingelheim’s tribulations at its US production site Ben Venue Laboratories are refusing to leave as more of its products …
InterMune stock jumps on suitor claims
August 14, 2014Sales and Marketing Boehringer, Esbriet, FDA, GSK, IPF, InterMune
Riding high of the success of its new lung drug Esbriet, InterMune has become the focus of some serious takeover …
BMJ investigation raises new concerns over Pradaxa
July 24, 2014Medical Communications, Research and Development, Sales and Marketing BMJ, Boehringer, Channel 4, Pradaxa, blood, warfarin
An investigation by The BMJ has raised fresh concerns about Boehringer’s top-selling blood thinner Pradaxa (dabigatran) and the regulatory decisions …
Hikma completes Bedford Laboratories purchase
July 16, 2014Manufacturing and Production Ben Venue, Boehringer, Hikma, bedford laboratories
Hikma has completed its acquisition of assets of the US generic injectables business Bedford Laboratories from Ben Venue Laboratories, a …
Boehringer blood cancer drug scores in Phase II
July 9, 2014Research and Development, Sales and Marketing Boehringer, blood, giotrif, leukaemia, volasertib
Less than a year after securing its first cancer drug on the market with Giotrif, Boehringer has taken another decisive …
Lilly launches online board game
June 24, 2014Medical Communications, Sales and Marketing Boehringer, Gamification, Syrum, destination discovery, lillypad
Eli Lilly has created an online board game called ‘Destination Discovery’ that it says can help users enjoy the challenges …
Boehringer abandons hep C
June 23, 2014Research and Development, Sales and Marketing AbbVie, Boehringer, HCV, faldaprevir, german, hep C
Boehringer Ingelheim has abandoned its hepatitis C (HCV) drug development programme as a dead loss after ‘re-evaluating’ its strategy. The …
Pradaxa gets DVT indication
June 6, 2014Sales and Marketing Boehringer, DVT, Pradaxa, blood, dabigatran etexilate, thinner
Pradaxa has been given approval in Europe to treat deep vein thrombosis (DVT) and pulmonary embolism (PE) just a week …
EMA accepts Boehringer IPF drug
June 6, 2014Sales and Marketing Boehringer, EMA, IPF, inpulsis, lung, nintedanib
Boehringer Ingelheim has moved a step closer to getting its investigational treatment nintedanib approved in Europe for a potentially fatal …
Boehringer lung cancer drug shows survival benefit
June 3, 2014Sales and Marketing ASCO, Boehringer, NSCLC, afatinib, giotrif, lung cancer
A new analysis of two late-stage trials shows that Boehringer drug Giotrif extends overall survival in a large proportion of …
Boehringer settles US lawsuits
May 29, 2014Medical Communications, Sales and Marketing Boehringer, Pradaxa, US, blood, lawsuits, warfarin
Boehringer Ingelheim has sought to bring to an end around 4,000 legal cases which have been brought against the company …
Latest content
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?
